Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6889704 | 0.95 | DRD2 (0.32) | DRD2CACNA1BCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL6889678 | 0.90 | BRD4 (0.31) | — | |
| Hydrochloric Acid SCHEMBL6891831 | 0.86 | BRD4 (0.33) | — | |
| Hydrochloric Acid SCHEMBL6893042 | 0.86 | ADRA2A (0.31) | — | |
| Hydrochloric Acid SCHEMBL6886226 | 0.86 | CHRNB2 (0.30) | — | |
| Hydrochloric Acid SCHEMBL6884503 | 0.85 | DRD2 (0.33) | DRD2CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL6888467 | 0.85 | BRD4 (0.32) | — | |
| Hydrochloric Acid SCHEMBL6892004 | 0.85 | GABBR2 (0.32) | DRD2CACNA1BCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL6892706 | 0.84 | CACNA1B (0.33) | DRD2CACNA1B | |
| Hydrochloric Acid SCHEMBL6891690 | 0.83 | EDNRB (0.31) | CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784305-B2 | DERIVATIVES OF ZIRCONOCENE DICHLORIDE IN WHICH THE TWO SUBSTITUTED INDENYL GROUPS ARE JOINED TO ONE ANOTHER VIA A BRIDGE CAN, OWING TO THEIR CONFORMATIONAL RIGIDITY, BE USED AS CATALYSTS FOR THE STEREOSPECIFIC POLYMERIZATION OF OLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2004-08-31 | — | — | US | disclosed |
| US-20030199703-A1 | Method for producing alkyl-bridged ligand systems and transition metal compounds | EQUISTAR CHEMICALS, LP | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199703-A1 | Method for producing alkyl-bridged ligand systems and transition metal compounds | ABL1, ICMT, ORAI2 | DRD2 1104/4885CACNA1B 462/4885CYP11B1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.